51. Rituximab for rheumatoid arthritis-related interstitial lung disease: A systematic review and meta-analysis.
- Author
-
Boppana, Tarun Krishna, Mittal, Saurabh, Madan, Karan, Mohan, Anant, Hadda, Vijay, and Guleria, Randeep
- Subjects
- *
MEDICAL information storage & retrieval systems , *PATIENT safety , *VITAL capacity (Respiration) , *DEATH , *RHEUMATOID arthritis , *RITUXIMAB , *INTERSTITIAL lung diseases , *TREATMENT effectiveness , *META-analysis , *SYSTEMATIC reviews , *MEDLINE , *DRUG efficacy , *ONLINE information services , *CONFIDENCE intervals , *TUMOR necrosis factors , *EVALUATION , *DISEASE risk factors , *DISEASE complications - Abstract
Objectives: This systematic review and meta-analysis aimed at summarizing the evidence of efficacy and safety of rituximab in rheumatoid arthritis-related interstitial lung disease (RA-ILD). Materials and methods: PubMed and Embase databases were searched until June 22, 2022, to identify studies on RA-ILD treated with rituximab, confined to predefined inclusion and exclusion criteria. A systematic review and meta-analysis were performed on the included studies to assess the overall stabilization or improvement in ILD, changes in percent-predicted (%-predicted) forced vital capacity (FVC), and %-predicted diffusion capacity of lungs for carbon monoxide (DLCO) following rituximab therapy. Results: A total of 15 studies (4 prospective and 11 retrospective studies) were included, with a total of 314 patients. There were 105 (60.7%) females out of 173 subjects for whom sex details were available from seven studies. The overall pooled proportion of patients with stabilization or improvement in ILD was 0.88 [95% confidence interval (CI): 0.76-0.96, p=0.02]. Rituximab improved FVC from baseline by 7.50% (95% CI: 1.35-13.65; p=0.02, fixed effect). Similarly, rituximab improved DLCO by 6.39% (95% CI: 1.366-14.43; p=0.12, random-effect). Two retrospective studies reported reduced mortality with rituximab therapy compared to tumor necrosis factor-alpha inhibitors. Conclusion: Treatment with rituximab in RA-ILD was associated with a significant improvement in %-predicted FVC, as well as stabilization or improvement in ILD after one year of treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF